Retinopathy of Prematurity Clinical Trials

Find Retinopathy of Prematurity Clinical Trials Near You

Elucidating Perifoveal Vasculature Development in Infants

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Observational
SUMMARY

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 2 months
Healthy Volunteers: f
View:

• Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian

• Parent/Legal Guardian is able and willing to consent to study participation for the infant

• Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit

Locations
United States
North Carolina
Duke University
RECRUITING
Durham
Pennsylvania
University of Pennsylvania
NOT_YET_RECRUITING
Philadelphi
Contact Information
Primary
Xi Chen, MD
xi2.chen@duke.edu
(919) 684-8434
Backup
Michelle N McCall
michelle.mccall@duke.edu
(919) 684-0544
Time Frame
Start Date: 2024-10-03
Estimated Completion Date: 2027-08-31
Participants
Target number of participants: 16
Treatments
Cohort 1
16 preterm infants undergoing ROP screening to optimize methods to acquire and process beside infant perifoveal vascular imaging and assess rigor and reproducibility.~The visits in the ICN (Intensive Care Nursery) will occur between 32 and 43 weeks post menstrual age at the time of ROP screening exams. Study visits will include, but are not limited to:~* Ocular examination~* OCT imaging of retinal microanatomy~* OCTA imaging of retinal microvasculature~* Medical and ocular history~* Adverse event documentation
Related Therapeutic Areas
Sponsors
Leads: Duke University
Collaborators: National Institutes of Health (NIH), University of Pennsylvania

This content was sourced from clinicaltrials.gov